ALPHATREX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Alphatrex, and what generic alternatives are available?
Alphatrex is a drug marketed by Savage Labs and is included in three NDAs.
The generic ingredient in ALPHATREX is betamethasone dipropionate. There are sixty-six drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Alphatrex
A generic version of ALPHATREX was approved as betamethasone dipropionate by FOUGERA PHARMS on June 26th, 1984.
US Patents and Regulatory Information for ALPHATREX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Savage Labs | ALPHATREX | betamethasone dipropionate | CREAM;TOPICAL | 019138-001 | Jun 26, 1984 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Savage Labs | ALPHATREX | betamethasone dipropionate | LOTION;TOPICAL | 070273-001 | Aug 12, 1985 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Savage Labs | ALPHATREX | betamethasone dipropionate | OINTMENT;TOPICAL | 019143-001 | Sep 4, 1984 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
